Bellicum Pharmaceuticals, Inc.
BLCM
BLCM was delisted on the 1st of June, 2023.
28 hedge funds and large institutions have $4.48M invested in Bellicum Pharmaceuticals, Inc. in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 3 closing their positions.
7% less funds holding
Funds holding: 30 → 28 (-2)
13% less capital invested
Capital invested by funds: $5.13M → $4.48M (-$647K)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$54.5K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$17.6K |
| 3 |
Morgan Stanley
New York
|
+$2.45K |
| 4 |
BlackRock
New York
|
+$973 |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$387 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Squarepoint
New York
|
-$54K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$47K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$13.5K |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$9.89K |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$9.89K |
BLCM Hedge Fund Activity: Q3 2021 in Review
28 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q3 2021, worth a combined $4.48M — down 13% from $5.13M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of BLCM and 1 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 5 added.
The largest buyer was Geode Capital Management, adding an estimated $54.5K. The largest seller was Squarepoint, exiting entirely with an estimated $54K sold.
- 28 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q3 2021, down from 30 in Q2 2021.
- Funds reported $4.48M of Bellicum Pharmaceuticals, Inc. stock for Q3 2021, down 13% quarter-over-quarter.
- 1 fund opened new Bellicum Pharmaceuticals, Inc. positions in Q3 2021 and 3 closed out, a net change of -2 holders.
- The largest Bellicum Pharmaceuticals, Inc. buyer in Q3 2021 was Geode Capital Management, an estimated $54.5K added.
- The largest Bellicum Pharmaceuticals, Inc. seller in Q3 2021 was Squarepoint, an estimated $54K sold.
Based on aggregated 13F filings for Q3 2021.